Generics - Remicade


Current filters:


Popular Filters

New phase of MAb biosimilars opportunities in Japan

New phase of MAb biosimilars opportunities in Japan


The launch of Remicade (infliximab, from Johnson & Johnson) biosimilar in December 2014 in the Japan…

BiosimilarserythropoietinGenericsJapanMarkets & MarketingRegulationRemicade

Nippon Kayaku launches biosimilar Remicade in Japan

Nippon Kayaku launches biosimilar Remicade in Japan


Japanese drugmaker Nippon Kayaku has launched the sale of Infliximab BS for IV Infusion 100mg, a biosimilar…

Anti-Arthritics/RheumaticsBiosimilarsGenericsinfliximabJapanJohnson & JohnsonMarkets & MarketingNippon KayakuRemicade

First biosimilar monoclonal antibody approved in Europe


US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

Phase III data support biosimilarity of BOW-015 to Remicade


Privately-held US biotech firm EPIRUS Biopharmaceuticals, which is focused on the development and production…

Anti-Arthritics/RheumaticsBiotechnologyEPIRUS BiopharmaceuticalsGenericsinfliximabRegulationRemicadeResearch

Uptake of biosimilars will see Remicade and Humira sales decline in 2017


The TNF-alpha inhibitors infliximab (Janssen Biotech/Merck/Mitsubishi Tanabe's Remicade) and adalimumab…

BiotechnologyGastro-intestinalsGenericsGlobalHumiraMarkets & MarketingRemicade

World's first (official) biosimilar antibody goes to reumatoid arthritis


The end of July 2012 proved exciting for the world of biosimilar manufacturers. However, for the regulatory…

BiotechnologyCellTrionGenericsGlobalinfliximabJohnson & JohnsonMarkets & MarketingRegulationRemicadeRemsima

Back to top